Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Breast Cancer Patients
Interventions: GENETIC: polymorphism analysis|DRUG: Doxorubicin-Cyclophosphamide regimen
Sponsor: Damanhour University
Collaborators: Al-Azhar University|National Cancer Institute, Egypt